Premium
IQVIA Holdings Inc (QTS)
TG
Hot Features
Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
| Date | Nom du détenteur | Actions transigées | Fourchette de valeur ($) | Type d'opération | Fourchette de prix ($) | Actions en fin de déclaration | % de variation |
|---|---|---|---|---|---|---|---|
| 2026-02-13 | Mr. Bernard HaasExec. VP of AI & Technology Solutions | -20,00 | 3,34k | Sale to Issuer | 166,94 | 17,02k | -0,12% |
| 2026-02-13 | Mr. Michael J. FedockExec. VP & CFO | -123,00 | 20,53k | Sale to Issuer | 166,94 | 6,63k | -1,82% |
| 2026-02-08 | Mr. Bernard HaasExec. VP of AI & Technology Solutions | -440,00 | 82,50k | Sale to Issuer | 187,49 | 16,67k | -2,57% |
| 2026-02-08 | Mr. Alistair GrenfellPresident of Commercial Solutions | -5,55k | 1,04M | Sale to Issuer | 187,49 | 24,12k | -18,69% |
| 2026-02-07 | Mr. Michael J. FedockExec. VP & CFO | -2,53k | 474,54k | Sale to Issuer | 187,49 | 6,47k | -28,13% |
| 2026-02-08 | Mr. Bhavik PatelPresident of MedTech & Consumer Health | -1,92k | 359,98k | Sale to Issuer | 187,49 | 3,20k | -37,48% |
| 2026-02-08 | Mr. Eric M. SherbetExec. VP, General Counsel & Secretary | -1,92k | 359,04k | Sale to Issuer | 187,49 | 26,00k | -6,86% |
| 2026-02-08 | Mr. W. Richard StaubPresident of Research & Development Solutions | -806,00 | 151,12k | Sale to Issuer | 187,49 | 18,81k | -4,11% |
| 2026-02-08 | Ms. Keriann CherofskySenior VP, Corporate Controller & CAO | -415,00 | 77,81k | Sale to Issuer | 187,49 | 1,09k | -27,57% |
| 2026-02-08 | Mr. Ronald E. BruehlmanInitié | -6,80k | 1,28M | Sale to Issuer | 187,49 | 56,00k | -10,83% |
| 2026-02-08 | Mr. James G. BerkshireExec. VP of Global Infrastructure & Operations | -1,28k | 239,99k | Sale to Issuer | 187,49 | 8,18k | -13,53% |
| 2026-02-08 | Mr. Ari BousbibCEO & Chairman | -28,40k | 5,32M | Sale to Issuer | 187,49 | 1,38M | -2,02% |
| 2026-01-28 | Mr. Michael J. FedockExec. VP & CFO | -381,00 | 91,35k | Sale to Issuer | 239,76 | 1,88k | -16,89% |
| 2025-12-18 | Mr. Ari BousbibCEO & Chairman | -50,00k | 8,13M | Derivative Exercise and Sale | 59,90 - 222,91 | 1,35M | - |
| 2025-10-29 | Mr. Eric M. SherbetExec. VP, General Counsel & Secretary | -10,00k | 878,92k | Derivative Exercise and Sale | 131,82 - 219,72 | 21,11k | - |
| 2025-10-29 | Mr. Ari BousbibCEO & Chairman | -77,59k | 12,46M | Derivative Exercise and Sale | 59,90 - 221,97 | 1,35M | - |
| 2025-07-28 | Mr. Bhavik PatelPresident of MedTech & Consumer Health | -84,00 | 16,61k | Sale to Issuer | 197,76 | 1,04k | -7,47% |
| 2025-07-28 | Ms. Keriann CherofskySenior VP, Corporate Controller & CAO | -35,00 | 6,92k | Sale to Issuer | 197,76 | 418,00 | -7,73% |
| 2025-07-23 | Ms. Keriann CherofskySenior VP, Corporate Controller & CAO | -549,00 | 105,15k | Vente | 191,53 | 353,00 | -60,86% |
| 2025-07-23 | Mr. Eric M. SherbetExec. VP, General Counsel & Secretary | -11,87k | 1,10M | Derivative Exercise and Sale | 97,20 - 190,10 | 21,11k | - |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
S'inscrire avec l'e-mail
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.
